A panel of three IHC markers—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)—are the most commonly used due to its predictive value for chemotherapy response in breast cancer [1]. This evidence concerns the gene ESR1 and breast carcinoma.